Verici is an immuno-diagnostics development company, primarily focused on kidney transplantation. Its kidney transplant assays use advanced next-generation sequencing to help define a personalised risk-profile of each patient over the course of their transplant journey, as well as to potentially detect injury in advance of clinical tests.
£14.5 million was raised through a placing, (£12m), share subscription (£2.1m) and restricted offer (£0.4m).
Nick McCarthy, corporate partner at BDB Pitmans led the transaction, and was assisted by senior associate Daniel King, solicitor Laura Crotch and trainee solicitor Emma Watson.
Commenting on the transaction, partner Nick McCarthy remarks: “The corporate team is delighted to have advised on another successful IPO and to secure an excellent outcome for the client in this challenging climate. It is also heartening to see the company open strongly in the first day of dealings.”